T-cell receptor gene therapy - ready to go viral?

Molecular Oncology

Volumn 9, Issue 10, 2015, Pages 2019-2042

  Karpanen, Terhi ^a   Olweus, Johanna ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer; Gene therapy; Immunotherapy; T cell; T cell receptor

Indexed keywords

INTERLEUKIN 2; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; GENE TARGETING; HEALTH CARE QUALITY; HLA SYSTEM; HUMAN; IN VITRO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; ANIMAL; GENE THERAPY; GENETICS; LYMPHOCYTE DEPLETION; MOUSE;

ANIMALS; GENETIC THERAPY; HUMANS; LYMPHOCYTE DEPLETION; MICE; RECEPTORS, ANTIGEN, T-CELL;

EID: 84952638435     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.10.006     Document Type: Review

References (237)

1. Abrahamsen I.W., Stronen E., Walchli S., Johansen J.N., Kjellevoll S., Kumari S., Komada M., Gaudernack G., Tjonnfjord G., Toebes M., Schumacher T.N., Lund-Johansen F., Olweus J. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 2010, 24:1901-1909.
2. Abrahamsen I.W., Kjellevoll S., Greve-Isdahl M., Mensali N., Walchli S., Kumari S., Loland B.F., Egeland T., Kolstad A., Olweus J. T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. Int. J. Cancer 2012, 130:1821-1832.
3. Ahmadi M., King J.W., Xue S.A., Voisine C., Holler A., Wright G.P., Waxman J., Morris E., Stauss H.J. CD3 limits the efficacy of TCR gene therapy in vivo. Blood 2011, 118:3528-3537.
4. Amir A.L., van der Steen D.M., Hagedoorn R.S., Kester M.G., van Bergen C.A., Drijfhout J.W., de Ru A.H., Falkenburg J.H., van Veelen P.A., Heemskerk M.H. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood 2011, 118:6733-6742.
5. Amir A.L., van der Steen D.M., van Loenen M.M., Hagedoorn R.S., de Boer R., Kester M.D., de Ru A.H., Lugthart G.J., van Kooten C., Hiemstra P.S., Jedema I., Griffioen M., van Veelen P.A., Falkenburg J.H., Heemskerk M.H. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin. Cancer Res. 2011, 17:5615-5625.
6. Andersen R.S., Thrue C.A., Junker N., Lyngaa R., Donia M., Ellebaek E., Svane I.M., Schumacher T.N., Thor Straten P., Hadrup S.R. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 2012, 72:1642-1650.
7. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., KlebanoffC.A., Overwijk W.W., Rosenberg S.A., Restifo N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174:2591-2601.
8. Araki K., Turner A.P., Shaffer V.O., Gangappa S., Keller S.A., Bachmann M.F., Larsen C.P., Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
9. Baker M. Reproducibility crisis: blame it on the antibodies. Nature 2015, 521:274-276.
10. Barrett D.M., Zhao Y., Liu X., Jiang S., Carpenito C., Kalos M., Carroll R.G., June C.H., Grupp S.A. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 2011, 22:1575-1586.
11. Bendle G.M., Linnemann C., Hooijkaas A.I., Bies L., de Witte M.A., Jorritsma A., Kaiser A.D., Pouw N., Debets R., Kieback E., Uckert W., Song J.Y., Haanen J.B., Schumacher T.N. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 2010, 16:565-570.
12. Bendle G.M., Linnemann C., Bies L., Song J.Y., Schumacher T.N. Blockade of TGF-beta signaling greatly enhances the efficacy of TCR gene therapy of cancer. J. Immunol. 2013, 191:3232-3239.
13. Berdien B., Mock U., Atanackovic D., Fehse B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 2014, 21:539-548.
14. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 2008, 118:294-305.
15. Berger C., Sommermeyer D., Hudecek M., Berger M., Balakrishnan A., Paszkiewicz P.J., Kosasih P.L., Rader C., Riddell S.R. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol. Res. 2015, 3:206-216.
16. Bialer G., Horovitz-Fried M., Ya'acobi S., Morgan R.A., Cohen C.J. Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol. 2010, 184:6232-6241.
17. Birnbaum M.E., Mendoza J.L., Sethi D.K., Dong S., Glanville J., Dobbins J., Ozkan E., Davis M.M., Wucherpfennig K.W., Garcia K.C. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 2014, 157:1073-1087.
18. Blankenstein T., Leisegang M., Uckert W., Schreiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr. Opin. Immunol. 2015, 33C:112-119.
19. Bobisse S., Rondina M., Merlo A., Tisato V., Mandruzzato S., Amendola M., Naldini L., Willemsen R.A., Debets R., Zanovello P., Rosato A. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 2009, 69:9385-9394.
20. Bos R., van Duikeren S., Morreau H., Franken K., Schumacher T.N., Haanen J.B., van der Burg S.H., Melief C.J., Offringa R. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 2008, 68:8446-8455.
21. Bossi G., Buisson S., Oates J., Jakobsen B.K., Hassan N.J. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol. Immunother. 2014, 63:437-448.
22. Bradbury A., Pluckthun A. Reproducibility: standardize antibodies used in research. Nature 2015, 518:27-29.
23. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., Taylor C., Yeh R., Bartido S., Borquez-Ojeda O., Olszewska M., Bernal Y., Pegram H., Przybylowski M., Hollyman D., Usachenko Y., Pirraglia D., Hosey J., Santos E., Halton E., Maslak P., Scheinberg D., Jurcic J., Heaney M., Heller G., Frattini M., Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
24. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., Bartido S., Stefanski J., Taylor C., Olszewska M., Borquez-Ojeda O., Qu J., Wasielewska T., He Q., Bernal Y., Rijo I.V., Hedvat C., Kobos R., Curran K., Steinherz P., Jurcic J., Rosenblat T., Maslak P., Frattini M., Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013, 5:177ra138.
25. Buchholz V.R., Flossdorf M., Hensel I., Kretschmer L., Weissbrich B., Graf P., Verschoor A., Schiemann M., Hofer T., Busch D.H. Disparate individual fates compose robust CD8+ T cell immunity. Science 2013, 340:630-635.
26. Bunse M., Bendle G.M., Linnemann C., Bies L., Schulz S., Schumacher T.N., Uckert W. RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol. Ther. 2014, 22:1983-1991.
27. Cameron B.J., Gerry A.B., Dukes J., Harper J.V., Kannan V., Bianchi F.C., Grand F., Brewer J.E., Gupta M., Plesa G., Bossi G., Vuidepot A., Powlesland A.S., Legg A., Adams K.J., Bennett A.D., Pumphrey N.J., Williams D.D., Binder-Scholl G., Kulikovskaya I., Levine B.L., Riley J.L., Varela-Rohena A., Stadtmauer E.A., Rapoport A.P., Linette G.P., June C.H., Hassan N.J., Kalos M., Jakobsen B.K. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 2013, 5:197ra103.
28. Cha E., Graham L., Manjili M.H., Bear H.D. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res. Treat. 2010, 122:359-369.
29. Chamoto K., Tsuji T., Funamoto H., Kosaka A., Matsuzaki J., Sato T., Abe H., Fujio K., Yamamoto K., Kitamura T., Takeshima T., Togashi Y., Nishimura T. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 2004, 64:386-390.
30. Chapuis A.G., Ragnarsson G.B., Nguyen H.N., Chaney C.N., Pufnock J.S., Schmitt T.M., Duerkopp N., Roberts I.M., Pogosov G.L., Ho W.Y., Ochsenreither S., WolflM., Bar M., Radich J.P., Yee C., Greenberg P.D. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 2013, 5:174ra127.
31. Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., Mellman I., Prindiville S.A., Viner J.L., Weiner L.M., Matrisian L.M. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 2009, 15:5323-5337.
32. Chervin A.S., Aggen D.H., Raseman J.M., Kranz D.M. Engineering higher affinity T cell receptors using a T cell display system. J. Immunol. Methods 2008, 339:175-184.
33. Chhabra A., Yang L., Wang P., Comin-Anduix B., Das R., Chakraborty N.G., Ray S., Mehrotra S., Yang H., Hardee C.L., Hollis R., Dorsky D.I., Koya R., Kohn D.B., Ribas A., Economou J.S., Baltimore D., Mukherji B. CD4+CD25-T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J. Immunol. 2008, 181:1063-1070.
34. Chinnasamy N., Wargo J.A., Yu Z., Rao M., Frankel T.L., Riley J.P., Hong J.J., Parkhurst M.R., Feldman S.A., Schrump D.S., Restifo N.P., Robbins P.F., Rosenberg S.A., Morgan R.A. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 2011, 186:685-696.
35. Chmielewski M., Hombach A.A., Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 2014, 257:83-90.
36. Chodon T., Comin-Anduix B., Chmielowski B., Koya R.C., Wu Z., Auerbach M., Ng C., Avramis E., Seja E., Villanueva A., McCannel T.A., Ishiyama A., Czernin J., Radu C.G., Wang X., Gjertson D.W., Cochran A.J., Cornetta K., Wong D.J., Kaplan-Lefko P., Hamid O., Samlowski W., Cohen P.A., Daniels G.A., Mukherji B., Yang L., Zack J.A., Kohn D.B., Heath J.R., Glaspy J.A., Witte O.N., Baltimore D., Economou J.S., Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 2014, 20:2457-2465.
37. Cieri N., Camisa B., Cocchiarella F., Forcato M., Oliveira G., Provasi E., Bondanza A., Bordignon C., Peccatori J., Ciceri F., Lupo-Stanghellini M.T., Mavilio F., Mondino A., Bicciato S., Recchia A., Bonini C. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013, 121:573-584.
38. Clay T.M., Custer M.C., Sachs J., Hwu P., Rosenberg S.A., Nishimura M.I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 1999, 163:507-513.
39. Cohen C.J., Zheng Z., Bray R., Zhao Y., Sherman L.A., Rosenberg S.A., Morgan R.A. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 2005, 175:5799-5808.
40. Cohen C.J., Zhao Y., Zheng Z., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006, 66:8878-8886.
41. Cohen C.J., Li Y.F., El-Gamil M., Robbins P.F., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007, 67:3898-3903.
42. Cohen C.J., Gartner J.J., Horovitz-Fried M., Shamalov K., Trebska-McGowan K., Bliskovsky V.V., Parkhurst M.R., Ankri C., Prickett T.D., Crystal J.S., Li Y.F., El-Gamil M., Rosenberg S.A., Robbins P.F. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 2015, 125:3981-3991.
43. Crompton J.G., Sukumar M., Roychoudhuri R., Clever D., Gros A., Eil R.L., Tran E., Hanada K., Yu Z., Palmer D.C., Kerkar S.P., Michalek R.D., Upham T., Leonardi A., Acquavella N., Wang E., Marincola F.M., Gattinoni L., Muranski P., Sundrud M.S., KlebanoffC.A., Rosenberg S.A., Fearon D.T., Restifo N.P. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015, 75:296-305.
44. Cui Y., Zhang H., Meadors J., Poon R., Guimond M., Mackall C.L. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009, 114:3831-3840.
45. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
46. Davis J.L., Theoret M.R., Zheng Z., Lamers C.H., Rosenberg S.A., Morgan R.A. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 2010, 16:5852-5861.
47. de Witte M.A., Coccoris M., Wolkers M.C., van den Boom M.D., Mesman E.M., Song J.Y., van der Valk M., Haanen J.B., Schumacher T.N. Targeting self-antigens through allogeneic TCR gene transfer. Blood 2006, 108:870-877.
48. de Witte M.A., Jorritsma A., Kaiser A., van den Boom M.D., Dokter M., Bendle G.M., Haanen J.B., Schumacher T.N. Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol. 2008, 181:5128-5136.
49. Di Stasi A., De Angelis B., Rooney C.M., Zhang L., Mahendravada A., Foster A.E., Heslop H.E., Brenner M.K., Dotti G., Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
50. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., Straathof K., Liu E., Durett A.G., Grilley B., Liu H., Cruz C.R., Savoldo B., Gee A.P., Schindler J., Krance R.A., Heslop H.E., Spencer D.M., Rooney C.M., Brenner M.K. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365:1673-1683.
51. Doudna J.A., Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346:1258096.
52. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
53. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R.M., Marincola F.M., Leitman S.F., Seipp C.A., Rogers-Freezer L., Morton K.E., Nahvi A., Mavroukakis S.A., White D.E., Rosenberg S.A. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 2002, 25:243-251.
54. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
55. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
56. Dudley M.E., Gross C.A., Langhan M.M., Garcia M.R., Sherry R.M., Yang J.C., Phan G.Q., Kammula U.S., Hughes M.S., Citrin D.E., Restifo N.P., Wunderlich J.R., Prieto P.A., Hong J.J., Langan R.C., Zlott D.A., Morton K.E., White D.E., Laurencot C.M., Rosenberg S.A. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 2010, 16:6122-6131.
57. Dummer W., Niethammer A.G., Baccala R., Lawson B.R., Wagner N., Reisfeld R.A., Theofilopoulos A.N. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 2002, 110:185-192.
58. Felix N.J., Allen P.M. Specificity of T-cell alloreactivity. Nat. Rev. Immunol. 2007, 7:942-953.
59. Frankel T.L., Burns W.R., Peng P.D., Yu Z., Chinnasamy D., Wargo J.A., Zheng Z., Restifo N.P., Rosenberg S.A., Morgan R.A. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J. Immunol. 2010, 184:5988-5998.
60. Gao L., Bellantuono I., Elsasser A., Marley S.B., Gordon M.Y., Goldman J.M., Stauss H.J. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95:2198-2203.
61. Gao L., Downs A.M., Stauss H.J. Immunotherapy with CTL restricted by nonself MHC. Methods Mol. Med. 2005, 109:215-228.
62. Gattinoni L., Finkelstein S.E., KlebanoffC.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., Surh C.D., Rosenberg S.A., Restifo N.P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
63. Gattinoni L., KlebanoffC.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S.E., Theoret M.R., Rosenberg S.A., Restifo N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 2005, 115:1616-1626.
64. Gattinoni L., Zhong X.S., Palmer D.C., Ji Y., Hinrichs C.S., Yu Z., Wrzesinski C., Boni A., Cassard L., Garvin L.M., Paulos C.M., Muranski P., Restifo N.P. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 2009, 15:808-813.
65. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., Almeida J.R., Gostick E., Yu Z., Carpenito C., Wang E., Douek D.C., Price D.A., June C.H., Marincola F.M., Roederer M., Restifo N.P. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011, 17:1290-1297.
66. Geng D., Kaczanowska S., Tsai A., Younger K., Ochoa A., Rapoport A.P., Ostrand-Rosenberg S., Davila E. TLR5 ligand-secreting T cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res. 2015, 75:1959-1971.
67. Gerlach C., Rohr J.C., Perie L., van Rooij N., van Heijst J.W., Velds A., Urbanus J., Naik S.H., Jacobs H., Beltman J.B., de Boer R.J., Schumacher T.N. Heterogeneous differentiation patterns of individual CD8+ T cells. Science 2013, 340:635-639.
68. Geukes Foppen M.H., Donia M., Svane I.M., Haanen J.B.A.G. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol. Oncol. 2015, 9:1918-1935.
69. GoffS.L., Johnson L.A., Black M.A., Xu H., Zheng Z., Cohen C.J., Morgan R.A., Rosenberg S.A., Feldman S.A. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol. Immunother. 2010, 59:1551-1560.
70. Gomez-Eerland R., Nuijen B., Heemskerk B., van Rooij N., van den Berg J.H., Beijnen J.H., Uckert W., Kvistborg P., Schumacher T.N., Haanen J.B., Jorritsma A. Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. Hum. Gene Ther. Methods 2014, 25:277-287.
71. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., Milone M.C., Levine B.L., June C.H. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509-1518.
72. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., Mulder G.E., Toebes M., Vesely M.D., Lam S.S., Korman A.J., Allison J.P., Freeman G.J., Sharpe A.H., Pearce E.L., Schumacher T.N., Aebersold R., Rammensee H.G., Melief C.J., Mardis E.R., Gillanders W.E., Artyomov M.N., Schreiber R.D. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
73. Haabeth O.A., Tveita A.A., Fauskanger M., Schjesvold F., Lorvik K.B., Hofgaard P.O., Omholt H., Munthe L.A., Dembic Z., Corthay A., Bogen B. How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?. Front. Immunol. 2014, 5:174.
74. Haidar J.N., Pierce B., Yu Y., Tong W., Li M., Weng Z. Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins 2009, 74:948-960.
75. Harndahl M., Rasmussen M., Roder G., Dalgaard Pedersen I., Sorensen M., Nielsen M., Buus S. Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur. J. Immunol. 2012, 42:1405-1416.
76. Hart D.P., Xue S.A., Thomas S., Cesco-Gaspere M., Tranter A., Willcox B., Lee S.P., Steven N., Morris E.C., Stauss H.J. Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Ther. 2008, 15:625-631.
77. Heemskerk B., Liu K., Dudley M.E., Johnson L.A., Kaiser A., Downey S., Zheng Z., Shelton T.E., Matsuda K., Robbins P.F., Morgan R.A., Rosenberg S.A. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther. 2008, 19:496-510.
78. Hervent A.S., De Keulenaer G.W. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int. J. Mol. Sci. 2012, 13:12268-12286.
79. Hiasa A., Hirayama M., Nishikawa H., Kitano S., Nukaya I., Yu S.S., Mineno J., Kato I., Shiku H. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells. Gene Ther. 2008, 15:695-699.
80. Hinrichs C.S., Restifo N.P. Reassessing target antigens for adoptive T-cell therapy. Nat. Biotechnol. 2013, 31:999-1008.
81. Hinrichs C.S., Spolski R., Paulos C.M., Gattinoni L., Kerstann K.W., Palmer D.C., KlebanoffC.A., Rosenberg S.A., Leonard W.J., Restifo N.P. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111:5326-5333.
82. Hinrichs C.S., Borman Z.A., Cassard L., Gattinoni L., Spolski R., Yu Z., Sanchez-Perez L., Muranski P., Kern S.J., Logun C., Palmer D.C., Ji Y., Reger R.N., Leonard W.J., Danner R.L., Rosenberg S.A., Restifo N.P. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17469-17474.
83. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
84. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5387-5392.
85. Holler P.D., Chlewicki L.K., Kranz D.M. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 2003, 4:55-62.
86. Holm A., Wu W., Lund-Johansen F. Antibody array analysis of labelled proteomes: how should we control specificity?. Nat. Biotechnol. 2012, 29:578-585.
87. Hoppes R., Ekkebus R., Schumacher T.N., Ovaa H. Technologies for MHC class I immunoproteomics. J. Proteomics 2010, 73:1945-1953.
88. Housset D., Malissen B. What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity?. Trends Immunol. 2003, 24:429-437.
89. Huang J., Wang Q.J., Yang S., Li Y.F., El-Gamil M., Rosenberg S.A., Robbins P.F. Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J. Immunother. 2011, 34:327-335.
90. Hughes M.S., Yu Y.Y., Dudley M.E., Zheng Z., Robbins P.F., Li Y., Wunderlich J., Hawley R.G., Moayeri M., Rosenberg S.A., Morgan R.A. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 2005, 16:457-472.
91. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J.A., Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 2008, 358:2698-2703.
92. Huseby E.S., White J., Crawford F., Vass T., Becker D., Pinilla C., Marrack P., Kappler J.W. How the T cell repertoire becomes peptide and MHC specific. Cell 2005, 122:247-260.
93. Ignatowicz L., Kappler J., Marrack P. The repertoire of T cells shaped by a single MHC/peptide ligand. Cell 1996, 84:521-529.
94. Jedema I., Falkenburg F. Allo-reactive T cells for the treatment of hematological malignancies. Mol. Oncol. 2015, 9:1894-1903.
95. John L.B., Devaud C., Duong C.P., Yong C.S., Beavis P.A., Haynes N.M., Chow M.T., Smyth M.J., Kershaw M.H., Darcy P.K. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 2013, 19:5636-5646.
96. Johnson L.A., Heemskerk B., Powell D.J., Cohen C.J., Morgan R.A., Dudley M.E., Robbins P.F., Rosenberg S.A. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 2006, 177:6548-6559.
97. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., Lee C.C., Restifo N.P., Schwarz S.L., Cogdill A.P., Bishop R.J., Kim H., Brewer C.C., Rudy S.F., VanWaes C., Davis J.L., Mathur A., Ripley R.T., Nathan D.A., Laurencot C.M., Rosenberg S.A. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
98. Jorritsma A., Gomez-Eerland R., Dokter M., van de Kasteele W., Zoet Y.M., Doxiadis I.I., Rufer N., Romero P., Morgan R.A., Schumacher T.N., Haanen J.P. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 2009, 110:3564-3572.
99. June C.H., Riddell S.R., Schumacher T.N. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 2015, 7:280ps287.
100. Kageyama S., Ikeda H., Miyahara Y., Imai N., Ishihara M., Saito K., Sugino S., Ueda S., Ishikawa T., Kokura S., Naota H., Ohishi K., Shiraishi T., Inoue N., Tanabe M., Kidokoro T., Yoshioka H., Tomura D., Nukaya I., Mineno J., Takesako K., Katayama N., Shiku H. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin. Cancer Res. 2015, 21:2268-2277.
101. Kalbasi A., Shrimali R.K., Chinnasamy D., Rosenberg S.A. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J. Immunother. 2010, 33:672-683.
102. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., June C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3:95ra73.
103. Kerkar S.P., Muranski P., Kaiser A., Boni A., Sanchez-Perez L., Yu Z., Palmer D.C., Reger R.N., Borman Z.A., Zhang L., Morgan R.A., Gattinoni L., Rosenberg S.A., Trinchieri G., Restifo N.P. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 2010, 70:6725-6734.
104. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., Leonardi A.J., Morgan R.A., Wang E., Marincola F.M., Trinchieri G., Rosenberg S.A., Restifo N.P. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 2011, 121:4746-4757.
105. Kerkar S.P., Sanchez-Perez L., Yang S., Borman Z.A., Muranski P., Ji Y., Chinnasamy D., Kaiser A.D., Hinrichs C.S., KlebanoffC.A., Scott C.D., Gattinoni L., Morgan R.A., Rosenberg S.A., Restifo N.P. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J. Immunother. 2011, 34:343-352.
106. Kessels H.W., van Den Boom M.D., Spits H., Hooijberg E., Schumacher T.N. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14578-14583.
107. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., Schumacher T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2001, 2:957-961.
108. Kessels H.W., Schepers K., van den Boom M.D., Topham D.J., Schumacher T.N. Generation of T cell help through a MHC class I-restricted TCR. J. Immunol. 2006, 177:976-982.
109. Kessler J.H., Melief C.J. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007, 21:1859-1874.
110. Kieke M.C., Shusta E.V., Boder E.T., Teyton L., Wittrup K.D., Kranz D.M. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5651-5656.
111. KlebanoffC.A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A.R., Finkelstein S.E., Palmer D.C., Antony P.A., Hwang S.T., Rosenberg S.A., Waldmann T.A., Restifo N.P. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9571-9576.
112. KlebanoffC.A., Acquavella N., Yu Z., Restifo N.P. Therapeutic cancer vaccines: are we there yet?. Immunol. Rev. 2011, 239:27-44.
113. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 2013, 31:71-75.
114. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., Yang J.C., Kammula U.S., Devillier L., Carpenter R., Nathan D.A., Morgan R.A., Laurencot C., Rosenberg S.A. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
115. Kochenderfer J.N., Dudley M.E., Carpenter R.O., Kassim S.H., Rose J.J., Telford W.G., Hakim F.T., Halverson D.C., Fowler D.H., Hardy N.M., Mato A.R., Hickstein D.D., Gea-Banacloche J.C., Pavletic S.Z., Sportes C., Maric I., Feldman S.A., Hansen B.G., Wilder J.S., Blacklock-Schuver B., Jena B., Bishop M.R., Gress R.E., Rosenberg S.A. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013, 122:4129-4139.
116. Kochenderfer J.N., Dudley M.E., Kassim S.H., Somerville R.P., Carpenter R.O., Stetler-Stevenson M., Yang J.C., Phan G.Q., Hughes M.S., Sherry R.M., Raffeld M., Feldman S., Lu L., Li Y.F., Ngo L.T., Goy A., Feldman T., Spaner D.E., Wang M.L., Chen C.C., Kranick S.M., Nath A., Nathan D.A., Morton K.E., Toomey M.A., Rosenberg S.A. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 2015, 33:540-549.
117. Kolstad A., Kumari S., Walczak M., Madsbu U., Hagtvedt T., Bogsrud T.V., Kvalheim G., Holte H., Aurlien E., Delabie J., Tierens A., Olweus J. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood 2015, 125:82-89.
118. Kronig H., Hofer K., Conrad H., Guilaume P., Muller J., Schiemann M., Lennerz V., Cosma A., Peschel C., Busch D.H., Romero P., Bernhard H. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int. J. Cancer 2009, 125:649-655.
119. Kuball J., Schmitz F.W., Voss R.H., Ferreira E.A., Engel R., Guillaume P., Strand S., Romero P., Huber C., Sherman L.A., Theobald M. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005, 22:117-129.
120. Kuball J., Dossett M.L., WolflM., Ho W.Y., Voss R.H., Fowler C., Greenberg P.D. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007, 109:2331-2338.
121. Kuball J., Hauptrock B., Malina V., Antunes E., Voss R.H., WolflM., Strong R., Theobald M., Greenberg P.D. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J. Exp. Med. 2009, 206:463-475.
122. Kumari S., Walchli S., Fallang L.E., Yang W., Lund-Johansen F., Schumacher T.N., Olweus J. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:403-408.
123. Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 2013, 21:904-912.
124. Lei F., Zhao B., Haque R., Xiong X., Budgeon L., Christensen N.D., Wu Y., Song J. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance. Cancer Res. 2011, 71:4742-4747.
125. Lesokhin A.M., Callahan M.K., Postow M.A., Wolchok J.D. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 2015, 7:280sr281.
126. Li Y., Bleakley M., Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 2005, 175:2261-2269.
127. Li Y., Moysey R., Molloy P.E., Vuidepot A.L., Mahon T., Baston E., Dunn S., Liddy N., Jacob J., Jakobsen B.K., Boulter J.M. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 2005, 23:349-354.
128. Li L.P., Lampert J.C., Chen X., Leitao C., Popovic J., Muller W., Blankenstein T. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 2010, 16:1029-1034.
129. Liddy N., Bossi G., Adams K.J., Lissina A., Mahon T.M., Hassan N.J., Gavarret J., Bianchi F.C., Pumphrey N.J., Ladell K., Gostick E., Sewell A.K., Lissin N.M., Harwood N.E., Molloy P.E., Li Y., Cameron B.J., Sami M., Baston E.E., Todorov P.T., Paston S.J., Dennis R.E., Harper J.V., Dunn S.M., Ashfield R., Johnson A., McGrath Y., Plesa G., June C.H., Kalos M., Price D.A., Vuidepot A., Williams D.D., Sutton D.H., Jakobsen B.K. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 2012, 18:980-987.
130. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., Litzky L., Bagg A., Carreno B.M., Cimino P.J., Binder-Scholl G.K., Smethurst D.P., Gerry A.B., Pumphrey N.J., Bennett A.D., Brewer J.E., Dukes J., Harper J., Tayton-Martin H.K., Jakobsen B.K., Hassan N.J., Kalos M., June C.H. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122:863-871.
131. Linnemann C., van Buuren M.M., Bies L., Verdegaal E.M., Schotte R., Calis J.J., Behjati S., Velds A., Hilkmann H., Atmioui D.E., Visser M., Stratton M.R., Haanen J.B., Spits H., van der Burg S.H., Schumacher T.N. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 2015, 21:81-85.
132. Logunova N.N., Viret C., Pobezinsky L.A., Miller S.A., Kazansky D.B., Sundberg J.P., Chervonsky A.V. Restricted MHC-peptide repertoire predisposes to autoimmunity. J. Exp. Med. 2005, 202:73-84.
133. Lu Y.C., Yao X., Li Y.F., El-Gamil M., Dudley M.E., Yang J.C., Almeida J.R., Douek D.C., Samuels Y., Rosenberg S.A., Robbins P.F. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol. 2013, 190:6034-6042.
134. Malecek K., Zhong S., McGary K., Yu C., Huang K., Johnson L.A., Rosenberg S.A., Krogsgaard M. Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. J. Immunol. Methods 2013, 392:1-11.
135. Malecek K., Grigoryan A., Zhong S., Gu W.J., Johnson L.A., Rosenberg S.A., Cardozo T., Krogsgaard M. Specific increase in potency via structure-based design of a TCR. J. Immunol. 2014, 193:2587-2599.
136. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 1998, 19:395-404.
137. Matsushita N., Pilon-Thomas S.A., Martin L.M., Riker A.I. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods 2008, 333:167-179.
138. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., Mahnke Y.D., Melenhorst J.J., Rheingold S.R., Shen A., Teachey D.T., Levine B.L., June C.H., Porter D.L., Grupp S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371:1507-1517.
139. Molldrem J.J., Lee P.P., Kant S., Wieder E., Jiang W., Lu S., Wang C., Davis M.M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 2003, 111:639-647.
140. Morgan R.A., Kakarla S. Genetic modification of T cells. Cancer J. 2014, 20:145-150.
141. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
142. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
143. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., Phan G.Q., Hughes M.S., Kammula U.S., Miller A.D., Hessman C.J., Stewart A.A., Restifo N.P., Quezado M.M., Alimchandani M., Rosenberg A.Z., Nath A., Wang T., Bielekova B., Wuest S.C., Akula N., McMahon F.J., Wilde S., Mosetter B., Schendel D.J., Laurencot C.M., Rosenberg S.A. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 2013, 36:133-151.
144. Morris E.C., Tsallios A., Bendle G.M., Xue S.A., Stauss H.J. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7934-7939.
145. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
146. Newberg M.H., Smith D.H., Haertel S.B., Vining D.R., Lacy E., Engelhard V.H. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 1996, 156:2473-2480.
147. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982, 155:1063-1074.
148. Obenaus M., Leitao C., Leisegang M., Chen X., Gavvovidis I., van der Bruggen P., Uckert W., Schendel D.J., Blankenstein T. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nat. Biotechnol. 2015, 33:402-407.
149. Ochi T., Fujiwara H., Okamoto S., An J., Nagai K., Shirakata T., Mineno J., Kuzushima K., Shiku H., Yasukawa M. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 2011, 118:1495-1503.
150. Okamoto S., Mineno J., Ikeda H., Fujiwara H., Yasukawa M., Shiku H., Kato I. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009, 69:9003-9011.
151. Okoye I., Wang L., Pallmer K., Richter K., Ichimura T., Haas R., Crouse J., Choi O., Heathcote D., Lovo E., Mauro C., Abdi R., Oxenius A., Rutschmann S., Ashton-Rickardt P.G. The protein LEM promotes CD8+ T cell immunity through effects on mitochondrial respiration. Science 2015, 348:995-1001.
152. Olive K.P., Tuveson D.A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res. 2006, 12:5277-5287.
153. Palmer D.C., Chan C.C., Gattinoni L., Wrzesinski C., Paulos C.M., Hinrichs C.S., Powell D.J., KlebanoffC.A., Finkelstein S.E., Fariss R.N., Yu Z., Nussenblatt R.B., Rosenberg S.A., Restifo N.P. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8061-8066.
154. Parkhurst M.R., Joo J., Riley J.P., Yu Z., Li Y., Robbins P.F., Rosenberg S.A. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 2009, 15:169-180.
155. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., Hughes M.S., Kammula U.S., Phan G.Q., Lim R.M., Wank S.A., Restifo N.P., Robbins P.F., Laurencot C.M., Rosenberg S.A. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19:620-626.
156. Paulos C.M., Wrzesinski C., Kaiser A., Hinrichs C.S., Chieppa M., Cassard L., Palmer D.C., Boni A., Muranski P., Yu Z., Gattinoni L., Antony P.A., Rosenberg S.A., Restifo N.P. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 2007, 117:2197-2204.
157. Pearce E.L., Walsh M.C., Cejas P.J., Harms G.M., Shen H., Wang L.S., Jones R.G., Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.
158. Perro M., Tsang J., Xue S.A., Escors D., Cesco-Gaspere M., Pospori C., Gao L., Hart D., Collins M., Stauss H., Morris E.C. Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther. 2010, 17:721-732.
159. Philip B., Kokalaki E., Mekkaoui L., Thomas S., Straathof K., Flutter B., Marin V., Marafioti T., Chakraverty R., Linch D., Quezada S.A., Peggs K.S., Pule M. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 2014, 124:1277-1287.
160. Pierce B.G., Hellman L.M., Hossain M., Singh N.K., Vander Kooi C.W., Weng Z., Baker B.M. Computational design of the affinity and specificity of a therapeutic T cell receptor. PLoS Comput. Biol. 2014, 10:e1003478.
161. Pittet M.J., Gati A., Le Gal F.A., Bioley G., Guillaume P., de Smedt M., Plum J., Speiser D.E., Cerottini J.C., Dietrich P.Y., Romero P., Zippelius A. Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J. Immunol. 2006, 176:2330-2336.
162. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., Shaheen M., ErnstoffM.S., Minor D., Salama A.K., Taylor M., Ott P.A., Rollin L.M., Horak C., Gagnier P., Wolchok J.D., Hodi F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372:2006-2017.
163. Prieto P.A., Durflinger K.H., Wunderlich J.R., Rosenberg S.A., Dudley M.E. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 2010, 33:547-556.
164. Provasi E., Genovese P., Lombardo A., Magnani Z., Liu P.Q., Reik A., Chu V., Paschon D.E., Zhang L., Kuball J., Camisa B., Bondanza A., Casorati G., Ponzoni M., Ciceri F., Bordignon C., Greenberg P.D., Holmes M.C., Gregory P.D., Naldini L., Bonini C. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 2012, 18:807-815.
165. Quezada S.A., Simpson T.R., Peggs K.S., Merghoub T., Vider J., Fan X., Blasberg R., Yagita H., Muranski P., Antony P.A., Restifo N.P., Allison J.P. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010, 207:637-650.
166. Radojcic V., Bezak K.B., Skarica M., Pletneva M.A., Yoshimura K., Schulick R.D., Luznik L. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol. Immunother. 2010, 59:137-148.
167. Rapoport A.P., Stadtmauer E.A., Binder-Scholl G.K., Goloubeva O., Vogl D.T., Lacey S.F., Badros A.Z., Garfall A., Weiss B., Finklestein J., Kulikovskaya I., Sinha S.K., Kronsberg S., Gupta M., Bond S., Melchiori L., Brewer J.E., Bennett A.D., Gerry A.B., Pumphrey N.J., Williams D., Tayton-Martin H.K., Ribeiro L., Holdich T., Yanovich S., Hardy N., Yared J., Kerr N., Philip S., Westphal S., Siegel D.L., Levine B.L., Jakobsen B.K., Kalos M., June C.H. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 2015, 21:914-921.
168. Ray S., Chhabra A., Chakraborty N.G., Hegde U., Dorsky D.I., Chodon T., von Euw E., Comin-Anduix B., Koya R.C., Ribas A., Economou J.S., Rosenberg S.A., Mukherji B. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin. Immunol. 2010, 136:338-347.
169. Restifo N.P., Gattinoni L. Lineage relationship of effector and memory T cells. Curr. Opin. Immunol. 2013, 25:556-563.
170. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., Huang J., Powell D.J., Rosenberg S.A. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 2004, 173:7125-7130.
171. Robbins P.F., Li Y.F., El-Gamil M., Zhao Y., Wargo J.A., Zheng Z., Xu H., Morgan R.A., Feldman S.A., Johnson L.A., Bennett A.D., Dunn S.M., Mahon T.M., Jakobsen B.K., Rosenberg S.A. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 2008, 180:6116-6131.
172. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Levy C.L., Li Y.F., El-Gamil M., Schwarz S.L., Laurencot C., Rosenberg S.A. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
173. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., Samuels Y., Rosenberg S.A. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19:747-752.
174. Robbins P.F., Kassim S.H., Tran T.L., Crystal J.S., Morgan R.A., Feldman S.A., Yang J.C., Dudley M.E., Wunderlich J.R., Sherry R.M., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Li Y.F., El-Gamil M., Rosenberg S.A. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-Reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 2015, 21:1019-1027.
175. Rosenberg S.A. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 2010, 18:1744-1745.
176. Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321.
177. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86:1159-1166.
178. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
179. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., Morton K.E., Laurencot C.M., Steinberg S.M., White D.E., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
180. Rubinstein M.P., Su E.W., Suriano S., Cloud C.A., Andrijauskaite K., Kesarwani P., Schwartz K.M., Williams K.M., Johnson C.B., Li M., Scurti G.M., Salem M.L., Paulos C.M., Garrett-Mayer E., Mehrotra S., Cole D.J. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8 T cells. Cancer Immunol. Immunother. 2015, 64:539-549.
181. Sadovnikova E., Stauss H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13114-13118.
182. Sadovnikova E., Jopling L.A., Soo K.S., Stauss H.J. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. 1998, 28:193-200.
183. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
184. Savage P., Gao L., Vento K., Cowburn P., Man S., Steven N., Ogg G., McMichael A., Epenetos A., Goulmy E., Stauss H.J. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 2004, 103:4613-4615.
185. Schmid D.A., Irving M.B., Posevitz V., Hebeisen M., Posevitz-Fejfar A., Sarria J.C., Gomez-Eerland R., Thome M., Schumacher T.N., Romero P., Speiser D.E., Zoete V., Michielin O., Rufer N. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 2010, 184:4936-4946.
186. Scholten K.B., Kramer D., Kueter E.W., Graf M., Schoedl T., Meijer C.J., Schreurs M.W., Hooijberg E. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 2006, 119:135-145.
187. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
188. Sena L.A., Li S., Jairaman A., Prakriya M., Ezponda T., Hildeman D.A., Wang C.R., Schumacker P.T., Licht J.D., Perlman H., Bryce P.J., Chandel N.S. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 2013, 38:225-236.
189. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., Richards D.R., McDonald-Smith G.P., Gao H., Hennessy L., Finnerty C.C., Lopez C.M., Honari S., Moore E.E., Minei J.P., Cuschieri J., Bankey P.E., Johnson J.L., Sperry J., Nathens A.B., Billiar T.R., West M.A., Jeschke M.G., Klein M.B., Gamelli R.L., Gibran N.S., Brownstein B.H., Miller-Graziano C., Calvano S.E., Mason P.H., Cobb J.P., Rahme L.G., Lowry S.F., Maier R.V., Moldawer L.L., Herndon D.N., Davis R.W., Xiao W., Tompkins R.G. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3507-3512.
190. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348:56-61.
191. Simpson A.A., Mohammed F., Salim M., Tranter A., Rickinson A.B., Stauss H.J., Moss P.A., Steven N.M., Willcox B.E. Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:21176-21181.
192. Sledzinska A., Menger L., BergerhoffK., Peggs K.S., Quezada S.A. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol. Oncol. 2015, 9:1936-1965.
193. Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk. Res. 2006, 30(Suppl. 1):S16-S21.
194. Sommermeyer D., Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J. Immunol. 2010, 184:6223-6231.
195. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., Stauss H.J., Theobald M. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2001, 2:962-970.
196. Stronen E., Abrahamsen I.W., Gaudernack G., Walchli S., Munthe E., Buus S., Johansen F.E., Lund-Johansen F., Olweus J. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells. Scand. J. Immunol. 2009, 69:319-328.
197. Szymczak A.L., Workman C.J., Wang Y., Vignali K.M., Dilioglou S., Vanin E.F., Vignali D.A. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 2004, 22:589-594.
198. Tahara H., Fujio K., Araki Y., Setoguchi K., Misaki Y., Kitamura T., Yamamoto K. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J. Immunol. 2003, 171:2154-2160.
199. Theobald M., Biggs J., Dittmer D., Levine A.J., Sherman L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11993-11997.
200. Theoret M.R., Cohen C.J., Nahvi A.V., Ngo L.T., Suri K.B., Powell D.J., Dudley M.E., Morgan R.A., Rosenberg S.A. Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum. Gene Ther. 2008, 19:1219-1232.
201. Thomas E.D., Lochte H.L., Lu W.C., Ferrebee J.W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 1957, 257:491-496.
202. Thomas S., Xue S.A., Bangham C.R., Jakobsen B.K., Morris E.C., Stauss H.J. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 2011, 118:319-329.
203. Topalian S.L., Solomon D., Avis F.P., Chang A.E., Freerksen D.L., Linehan W.M., Lotze M.T., Robertson C.N., Seipp C.A., Simon P., et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 1988, 6:839-853.
204. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
205. Torikai H., Reik A., Liu P.Q., Zhou Y., Zhang L., Maiti S., Huls H., Miller J.C., Kebriaei P., Rabinovitch B., Lee D.A., Champlin R.E., Bonini C., Naldini L., Rebar E.J., Gregory P.D., Holmes M.C., Cooper L.J. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012, 119:5697-5705.
206. Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.C., Dudley M.E., Wunderlich J.R., Somerville R.P., Hogan K., Hinrichs C.S., Parkhurst M.R., Yang J.C., Rosenberg S.A. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344:641-645.
207. Udaka K., Tsomides T.J., Eisen H.N. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 1992, 69:989-998.
208. Uhlen M., Fagerberg L., Hallstrom B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson A., Kampf C., Sjostedt E., Asplund A., Olsson I., Edlund K., Lundberg E., Navani S., Szigyarto C.A., Odeberg J., Djureinovic D., Takanen J.O., Hober S., Alm T., Edqvist P.H., Berling H., Tegel H., Mulder J., Rockberg J., Nilsson P., Schwenk J.M., Hamsten M., von Feilitzen K., Forsberg M., Persson L., Johansson F., Zwahlen M., von Heijne G., Nielsen J., Ponten F. Proteomics. Tissue-based map of the human proteome. Science 2015, 347:1260419.
209. van den Berg J.H., Gomez-Eerland R., van de Wiel B., HulshoffL., van den Broek D., Bins A., Tan H.L., Harper J.V., Hassan N.J., Jakobsen B.K., Jorritsma A., Blank C.U., Schumacher T.N., Haanen J.B. Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Mol. Ther. 2015, 23:1541-1550.
210. van der Burg S.H., Visseren M.J., Brandt R.M., Kast W.M., Melief C.J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 1996, 156:3308-3314.
211. van der Windt G.J., Everts B., Chang C.H., Curtis J.D., Freitas T.C., Amiel E., Pearce E.J., Pearce E.L. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 2012, 36:68-78.
212. van Loenen M.M., de Boer R., Amir A.L., Hagedoorn R.S., Volbeda G.L., Willemze R., van Rood J.J., Falkenburg J.H., Heemskerk M.H. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10972-10977.
213. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El Atmioui D., Nieuwland M., Stratton M.R., Kerkhoven R.M., Kesmir C., Haanen J.B., Kvistborg P., Schumacher T.N. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 2013, 31:e439-442.
214. Vatakis D.N., Arumugam B., Kim S.G., Bristol G., Yang O., Zack J.A. Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol. Ther. 2013, 21:1055-1063.
215. Vera J.F., Hoyos V., Savoldo B., Quintarelli C., Giordano Attianese G.M., Leen A.M., Liu H., Foster A.E., Heslop H.E., Rooney C.M., Brenner M.K., Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol. Ther. 2009, 17:880-888.
216. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 1991, 173:1007-1015.
217. Wang L.X., Westwood J.A., Moeller M., Duong C.P., Wei W.Z., Malaterre J., Trapani J.A., Neeson P., Smyth M.J., Kershaw M.H., Darcy P.K. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res. 2010, 70:9591-9598.
218. Wang X., Chang W.C., Wong C.W., Colcher D., Sherman M., Ostberg J.R., Forman S.J., Riddell S.R., Jensen M.C. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011, 118:1255-1263.
219. Whilding L.M., Maher J. CAR T-cell immunotherapy: the path from the by-road to the freeway?. Mol. Oncol. 2015, 9:1994-2018.
220. Whitelegg A.M., Oosten L.E., Jordan S., Kester M., van Halteren A.G., Madrigal J.A., Goulmy E., Barber L.D. Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers. J. Immunol. 2005, 175:1706-1714.
221. Wick D.A., Webb J.R., Nielsen J.S., Martin S.D., Kroeger D.R., Milne K., Castellarin M., Twumasi-Boateng K., Watson P.H., Holt R.A., Nelson B.H. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 2014, 20:1125-1134.
222. Wilde S., Sommermeyer D., Frankenberger B., Schiemann M., Milosevic S., Spranger S., Pohla H., Uckert W., Busch D.H., Schendel D.J. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 2009, 114:2131-2139.
223. Willemsen R., Ronteltap C., Heuveling M., Debets R., Bolhuis R. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. Gene Ther. 2005, 12:140-146.
224. Wooldridge L., Ekeruche-Makinde J., van den Berg H.A., Skowera A., Miles J.J., Tan M.P., Dolton G., Clement M., Llewellyn-Lacey S., Price D.A., Peakman M., Sewell A.K. A single autoimmune T cell receptor recognizes more than a million different peptides. J. Biol. Chem. 2012, 287:1168-1177.
225. Wu C.Y., Roybal K.T., Puchner E.M., Onuffer J., Lim W.A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015, 350. aab4077.
226. Xie Y., Akpinarli A., Maris C., Hipkiss E.L., Lane M., Kwon E.K., Muranski P., Restifo N.P., Antony P.A. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 2010, 207:651-667.
227. Xu Y., Zhang M., Ramos C.A., Durett A., Liu E., Dakhova O., Liu H., Creighton C.J., Gee A.P., Heslop H.E., Rooney C.M., Savoldo B., Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014, 123:3750-3759.
228. Xue S.A., Gao L., Hart D., Gillmore R., Qasim W., Thrasher A., Apperley J., Engels B., Uckert W., Morris E., Stauss H. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005, 106:3062-3067.
229. Yang S., Cohen C.J., Peng P.D., Zhao Y., Cassard L., Yu Z., Zheng Z., Jones S., Restifo N.P., Rosenberg S.A., Morgan R.A. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008, 15:1411-1423.
230. Yang S., Dudley M.E., Rosenberg S.A., Morgan R.A. A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J. Immunother. 2010, 33:648-658.
231. Yang S., Gattinoni L., Liu F., Ji Y., Yu Z., Restifo N.P., Rosenberg S.A., Morgan R.A. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol. Immunother. 2011, 60:739-749.
232. Yang S., Ji Y., Gattinoni L., Zhang L., Yu Z., Restifo N.P., Rosenberg S.A., Morgan R.A. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother. 2013, 62:727-736.
233. Yao X., Ahmadzadeh M., Lu Y.C., Liewehr D.J., Dudley M.E., Liu F., Schrump D.S., Steinberg S.M., Rosenberg S.A., Robbins P.F. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012, 119:5688-5696.
234. Zeh H.J., Perry-Lalley D., Dudley M.E., Rosenberg S.A., Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 1999, 162:989-994.
235. Zhao Y., Bennett A.D., Zheng Z., Wang Q.J., Robbins P.F., Yu L.Y., Li Y., Molloy P.E., Dunn S.M., Jakobsen B.K., Rosenberg S.A., Morgan R.A. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 2007, 179:5845-5854.
236. Zhou P., Shaffer D.R., Alvarez Arias D.A., Nakazaki Y., Pos W., Torres A.J., Cremasco V., Dougan S.K., Cowley G.S., Elpek K., Brogdon J., Lamb J., Turley S.J., Ploegh H.L., Root D.E., Love J.C., DranoffG., Hacohen N., Cantor H., Wucherpfennig K.W. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 2014, 506:52-57.
237. Zhou Q., Facciponte J., Jin M., Shen Q., Lin Q. Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett. 2014, 344:13-19.